生物制剂治疗是否影响银屑病患者银屑病关节炎的发生
多变量校正后生物制剂使用与PsA发生风险升高相关(HR 4.48, 95%CI 4.23-4.75),倾向评分匹配后HR为2.14(95%CI 2.00-2.28),但可能存在适应证混杂和原发病偏倚。
要点
- 生物制剂使用与银屑病患者发生PsA风险升高相关,匹配后HR 2.14。
- 生物制剂使用者PsA发病率为77.26/1000人年,高于口服药或光疗者。
- 结果可能受适应证混杂和原发病偏倚影响,需前瞻性研究验证。
核心结论
- 在银屑病患者中,生物制剂使用与PsA的发生相关,但可能受适应证混杂和原发病偏倚影响。
研究设计与样本
- 回顾性队列研究,使用OptumInsights电子健康记录数据库2006-2017年数据,纳入16-90岁开始银屑病治疗(口服、生物制剂或光疗)的患者。
- 采用多变量Cox模型(生物制剂作为时变暴露)和倾向评分匹配队列计算风险比。
主要发现
- 生物制剂启动者平均年龄45.9岁,口服药或光疗启动者平均年龄49.8岁。
- 无论治疗暴露如何,PsA总发病率为9.75/1000人年;生物制剂使用者为77.26/1000人年,口服药使用者为61.99/1000人年,光疗使用者为26.11/1000人年,未使用目标治疗者为5.85/1000人年。
- 多变量校正时变暴露分析中,生物制剂使用者相比口服药或光疗使用者的校正HR为4.48(95%CI 4.23-4.75)。
- 倾向评分匹配后,HR为2.14(95%CI 2.00-2.28)。
临床怎么用
- 对于银屑病患者,使用生物制剂时应关注PsA的发生风险,但需注意研究结果可能受混杂影响。
局限性
- 回顾性队列设计可能引入适应证混杂和原发病偏倚。
- 需要前瞻性研究来进一步验证生物制剂使用与PsA发生的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the association of biologic therapy use for psoriasis with incident psoriatic arthritis (PsA) diagnosis. METHODS: A retrospective cohort study was conducted in the OptumInsights Electronic Health Record Database between 2006 and 2017 among patients with psoriasis between the ages of 16 and 90 initiating a therapy for psoriasis (oral, biologic or phototherapy). The incidence of PsA was calculated within each therapy group. Multivariable Cox models were used to calculate the HR for biologic versus oral or phototherapy using biologics as a time-varying exposure and next in a propensity score-matched cohort. RESULTS: Among 1 93 709 patients with psoriasis without PsA, 14 569 biologic and 20 321 cumulative oral therapy and phototherapy initiations were identified. Mean age was lower among biologic initiators compared with oral/phototherapy initiators (45.9 vs 49.8). The incidence of PsA regardless of therapy exposure was 9.75 per 1000 person-years compared with 77.26 among biologic users, 61.99 among oral therapy users, 26.11 among phototherapy users and 5.85 among those without a prescription for one of the target therapies. Using a multivariable adjustment approach with time-varying exposure, adjusted HR (95% CI) for biologic users was 4.48 (4.23 to 4.75) compared with oral or phototherapy users. After propensity score matching, the HR (95% CI) was 2.14 (2.00 to 2.28). CONCLUSIONS: In this retrospective cohort study, biologic use was associated with the development of PsA among patients with psoriasis. This may be related to confounding by indication and protopathic bias. Prospective studies are needed to address this important question.
引用
- Meer E, Merola JF, Fitzsimmons R, et al. Does biologic therapy impact the development of PsA among patients with psoriasis? Ann Rheum Dis. 2021. PMID: 34615637. doi:10.1136/annrheumdis-2021-220761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。